ORLANDO -- Major cardiovascular event risk in patients with inflammatory bowel disease (IBD) was no greater with Janus kinase (JAK) inhibitors than with tumor necrosis factor (TNF) inhibitors ...

Despite initial clinical data showing efficacy, Genmab has decided to discontinue further clinical development of ...

BALTIMORE, April 16, 2025--(BUSINESS WIRE)--TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) ("TNF" or the "Company"), a clinical stage biopharmaceutical company committed to ...

BALTIMORE--(BUSINESS WIRE)--TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) (“TNF” or the “Company”), a clinical stage biopharmaceutical company committed to ...

Treatment with CM313, a novel anti-CD38 monoclonal antibody, can result in targeted clearance of CD38-positive cells, including plasma cells. We conducted a phase 1–2, open-label study to ...

A new study published recently in the journal Gut shows children with Crohn's who were prescribed anti-TNF (tumor necrosis factor) drugs following their diagnosis had an 82% lower risk of anal ...

Earlier research by the same group had found that starting anti-TNF drugs as a first line of treatment reduced the likelihood of the patient developing a perianal fistula by about 60%. (And among ...

BALTIMORE, July 22, 2024--(BUSINESS WIRE)--TNF Pharmaceuticals, Inc., formerly MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (the "Company"), a clinical stage ...

Despite initial clinical data showing efficacy, Genmab has decided to discontinue further clinical development of HexaBody-CD38. “While we are disappointed that J&J has decided not to advance ...